ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Synergistic mechanisms and clinical translation of regorafenib combination therapies.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The evolution of regorafenib from a monotherapy to a cornerstone of combination regimens for advanced solid tumors is fueled by its unique multi-targeted profile. This review systematically delineates the synergistic mechanisms underpinning this evolution, encompassing the potent induction of diverse cell death programs (apoptosis, autophagy, ferroptosis), the vertical and horizontal blockade of oncogenic signaling pathways (MAPK, PI3K/AKT, STAT3), and the critical remodeling of the TME. These mechanistic rationales are critically translated into clinical practice, with combinations, particularly with immune checkpoint inhibitors, demonstrating breakthrough efficacy in challenging settings such as microsatellite-stable colorectal cancer and hepatocellular carcinoma. We further synthesize strategies to overcome resistance-from targeting compensatory pathways to employing novel nanocarriers for optimized drug delivery-and outline the future landscape, emphasizing the imperative for biomarker-driven patient selection and the integration of next-generation agents.
Indexed as
Identifiers
41526587What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.